All Articles

A renewable energy company's leap into mining raises questions. Is it brilliant vertical integration or a high-risk gamble diluting its green mission?

At ASH 2025, Bristol Myers Squibb didn't just show new drugs; it unveiled a powerful strategy combining cell therapy and protein degradation.

Beyond the hire, Coalition's new product chief from Nubank signals a strategic bet on proactive prevention over reactive payout in the war on digital risk.

With staggering revenue growth, key partnerships, and a TSX uplisting, this food-tech innovator is disrupting the global food supply chain.

ProMIS Neurosciences' bet on plasma pTau could make Alzheimer's trials faster and cheaper, giving its unique drug PMN310 a critical edge.

With $4.25M in new financing, Pulse Oil is betting big on EOR to revive a mature oilfield. Early data shows a 20% production jump.

Post's new $1.3B bond deal extends its debt maturity but at a higher cost. We analyze the market's mixed reaction and what it means for future growth.

Medicus Pharma consolidates its C-suite, naming a dual President/CFO to steer its high-stakes push in oncology, urology, and next-gen vaccines.

Endeavour Silver's massive convertible note offering is a dual play: shedding costly debt while fueling its giant Pitarrilla silver project in Mexico.

TPVG just locked in cheaper, long-term capital. We analyze why this move signals deep confidence in the future of AI and software innovation.

A wealth manager's regulatory filing reveals its strategic play in the Empiric Student Property takeover, offering a rare look at M&A endgame tactics.

With revenue soaring and losses cut, Hypercharge's real story is a strategic shift to higher-margin services and carbon credits. Here's why it matters.

A Houston biotech is targeting a devastating cancer complication with a novel radiotherapy. Can REYOBIQ™ change the grim prognosis for leptomeningeal metastases?

A permit delay at a historic silver mine in Peru tests Carlton Precious, highlighting the clash between rich resources and tough environmental rules.

The FDA accelerates a novel immunotherapy for acute myeloid leukemia. Its unique ability to target all FLT3 forms could change the treatment paradigm.

A new alliance aims to use quantum computing to slash the cost and time of creating advanced therapies. But how far are we from qubits to actual cures?

A tiny 0.12% stake disclosure seems trivial, but it offers a masterclass in reading M&A signals—a vital skill for investors in any sector.

Bicara Therapeutics' latest data for its dual-action antibody shows impressive consistency, de-risking its pivotal trial for a tough head and neck cancer.

After past stumbles, Merck unveils two new Alzheimer's candidates targeting different pathways, a high-stakes bet signaling a major strategic shift.

In the shadow of giants, a junior miner uses advanced geophysics to de-risk its hunt for a major discovery in the prolific Vicuña District.